Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Shipments Restricted or Halted for 22.9% of Products in August: FPMAJ
Shipments were restricted or suspended for 22.9% of all products in Japan in August, virtually unchanged from 22.4% the prior month, according to the latest supply survey conducted by the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ). For generic…
To read the full story
Related Article
- Shipments Restricted or Halted for 26.6% of Drugs in February: FPMAJ
March 21, 2024
- Shipments Curbed or Suspended for 25.9% of Drugs in January: FPMAJ
February 19, 2024
- Shipments Curbed or Suspended for 22.9% of Products in September: FPMAJ
October 27, 2023
- Shipments Restricted or Suspended for 22.4% of Products in July, No Sign of Improvement: FPMAJ
August 31, 2023
- Shipments of 22.3% of Products Restricted or Suspended in June: FPMAJ
July 24, 2023
- Supplies of 15% of Drugs Restricted, Generics Account for 80%: FPMAJ
May 24, 2023
- Over 20% of All Generics under Restricted Shipments: FPMAJ
March 14, 2023
- FPMAJ Calls on Drug Makers to Lift Shipment Controls of 233 APIs/Specifications
December 28, 2022
- FPMAJ Poll Finds Worsening Supply Woes with 28% of Drugs Restricted or Suspended
December 7, 2022
- 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
ORGANIZATION
- Labor Group Urges Govt to Scrap FY2027 Off-Year Drug Price Cuts
July 7, 2026
- Japan’s Contract Rep Workforce Hits Record High in FY2025
July 6, 2026
- Japan’s Generic Use Rate Climbs to 89.7% in FY2025: JGA
July 6, 2026
- FPMAJ Sets Up Drug Security Task Force under Chairman
July 3, 2026
- JETRO Opens 2026 Applications for Regenerative Medicine Program
July 2, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…